ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) In 2022: Is This Company Worth Thinking About Investing In? – Marketing Sentinel
Home  »  Company   »  ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) In 2022...

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) In 2022: Is This Company Worth Thinking About Investing In?

In today’s recent session, 1.6 million shares of the ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) have been traded, and its beta is 0.44. Most recently the company’s share price was $13.25, and it changed around $0.24 or 1.84% from the last close, which brings the market valuation of the company to $2.10B. ACAD at last check was trading at a discount to its 52-week high of $28.06, offering almost -111.77% off that amount. The share price’s 52-week low was $12.24, which indicates that the recent value has risen by an impressive 7.62% since then. We note from ACADIA Pharmaceuticals Inc.’s average daily trading volume that its 3-month average coming to 2.41 million.

ACADIA Pharmaceuticals Inc. stock received a consensus recommendation rating of an Overweight, based on a mean score of 2.40. If we narrow it down even further, the data shows that 1 out of 21 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 12 recommended ACAD as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. ACADIA Pharmaceuticals Inc. is expected to report earnings per share of -$0.24 for the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) trade information

Instantly ACAD has been showing a green trend so far today with a performance of 1.84% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 20.35 on Tuesday, 06/21/22 increased the stock’s daily price by 34.89%. The company’s shares are currently down -44.26% year-to-date, but still down -23.87% over the last five days. On the other hand, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is -18.89% down in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $22.56, which translates to bulls needing to increase their stock price by 41.27% from its current value. Analyst projections state that ACAD is forecast to be at a low of $10.00 and a high of $32.00. In order for the stock price to hit the forecast high, the stock would need to plunge -141.51% from its current level, while the stock would need to crash 24.53% from its current level to reach the projected low.

ACADIA Pharmaceuticals Inc. (ACAD) estimates and forecasts

ACADIA Pharmaceuticals Inc. share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -47.52 percent over the past six months and at a -34.29% annual growth rate that is well below the industry average of 0.60%. Moreover, analysts have decided to roll up on their fiscal year 2022 revenue estimates. The rating firms predict that it will gain 11.10% in revenue this quarter, and will report a decrease of -133.30% in the next quarter. The year-over-year growth rate is expected to be 10.10%, up from the previous year.

Consensus estimates provided by 17 financial analysts predict the company will bring in an average of $130.84 million in revenue for the current quarter. 17 analysts expect ACADIA Pharmaceuticals Inc. to make $140.85 million in revenue for the quarter ending Sep 2022. Analysts predict that the company’s current quarter sales will jump, forecast at 4.70%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 14.90%. ACADIA Pharmaceuticals Inc. earnings are expected to increase by 41.60% in 2022, but the outlook is positive 25.00% per year for the next five years.

ACAD Dividends

ACADIA Pharmaceuticals Inc.’s next quarterly earnings report is expected to be released around February 22 and February 28.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 0.42% of ACADIA Pharmaceuticals Inc. shares, and 91.60% of them are in the hands of institutional investors. The stock currently has a share float of 91.98%. ACADIA Pharmaceuticals Inc. stock is held by 360 institutions, with Baker Brothers Advisors, LLC being the largest institutional investor. By Dec 30, 2021, it held 25.96% of the shares, which is about 41.91 million shares worth $978.2 million.

FMR, LLC, with 8.57% or 13.84 million shares worth $323.04 million as of Dec 30, 2021, holds the second largest percentage of outstanding shares.

Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Feb 27, 2022. The former held 5.1 million shares worth $129.54 million, making up 3.16% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 3.43 million shares worth around $80.05 million, which represents about 2.12% of the total shares outstanding.

Leave a Comment

Your email address will not be published.

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]